Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases.
Leili BehroozCarrie G LennemanNaomi M HamburgPublished in: Current cardiology reports (2023)
Robust evidence demonstrates the burden of obesity across the lifespan in women and links obesity to a diverse set of cardiovascular diseases. Female-specific risk factors including sex hormones and pregnancy factors intersect with obesity and cardiovascular risk. Sustained weight loss has potential for cardiovascular benefits. Recent trials demonstrate cardiovascular benefits of emerging agents with weight loss effects including GLP-1 RA and SGLT2 inhibitors in women. Treatment and prevention strategies for cardiovascular disease in obese women should include integration of weight management strategies including the targeted use of emerging pharmacologic therapies.
Keyphrases
- weight loss
- cardiovascular disease
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- polycystic ovary syndrome
- risk factors
- pregnancy outcomes
- insulin resistance
- metabolic syndrome
- weight gain
- type diabetes
- glycemic control
- obese patients
- healthcare
- high fat diet induced
- pregnant women
- cervical cancer screening
- rheumatoid arthritis
- adipose tissue
- cardiovascular events
- body mass index
- breast cancer risk
- preterm birth
- coronary artery disease
- systemic sclerosis
- drug delivery
- replacement therapy
- disease activity